Cambridge University Hospitals NHS Foundation Trust

cuh.nhs.uk

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

166

Active

32

Phase 3

21

Total enrollment

181,605

Pipeline matrix

Showing 16 of 16 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Tirzepatide2
semaglutide1
Olaparib3
Paclitaxel and Carboplatin1
Phenytoin Sodium1
Levetiracetam1
Ibudilast1
dapansutrile1
Apalutamide Oral Tablet [Erleada]1
Pembrolizumab1
Belzutifan1
Aldesleukin3
Interleukin-2 [IL-2]2
Interleukin-21
Anti-Hypertensive medications1
Dextrose 5% in water1

Next readouts

  • 2024-06
  • 2025-02-01
  • 2026-03-01
  • 2026-09-01
  • 2027-01
  • 2027-04
  • 2027-04
  • 2027-04-30
  • 2027-05
  • 2027-07-31

Top conditions

  • Cardiovascular Diseases10
  • Breast Cancer9
  • Prostate Cancer6
  • Stroke4
  • Covid194
  • COVID-194
  • Hypertension4
  • Microscopic Polyangiitis4

Frequently asked questions about Cambridge University Hospitals NHS Foundation Trust

How many clinical trials does Cambridge University Hospitals NHS Foundation Trust have on ClinicalTrials.gov?
Cambridge University Hospitals NHS Foundation Trust is listed as the lead sponsor on 166 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
How many of Cambridge University Hospitals NHS Foundation Trust's trials are in Phase 3?
21 of Cambridge University Hospitals NHS Foundation Trust's trials are in Phase 3, spread across 16 active drug programs.
What therapeutic areas does Cambridge University Hospitals NHS Foundation Trust focus on?
Cambridge University Hospitals NHS Foundation Trust's most-studied conditions on ClinicalTrials.gov are Cardiovascular Diseases, Breast Cancer, Prostate Cancer, Stroke, Covid19.
When are Cambridge University Hospitals NHS Foundation Trust's next clinical trial readouts?
Cambridge University Hospitals NHS Foundation Trust has 10 upcoming primary-completion readouts tracked here; the soonest is “Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer”, expected around 2024-06.